<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="523">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>21/09/2005</approvaldate>
  <actrnumber>ACTRN12605000452695</actrnumber>
  <trial_identification>
    <studytitle>Adoptive immunotherapy for the prevention of Human Cytomegalovirus (HCMV) reactivation and disease after Allogenic Stem Cell Transplantation</studytitle>
    <scientifictitle>A phase I/II study to evaluate the effect of a single dose of human Cytomegalovirus (HCMV)-specific bulk cytotoxic T lymphocytes (CTL) to prevent complications associated with HCMV reactivation following allogeneic stem cell transplantation</scientifictitle>
    <utrn />
    <trialacronym>QR2002-CMV1</trialacronym>
    <secondaryid>Queensland Institute of Medical Research (QIMR): QIMR P395</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Human Cytomegalovirus (HCMV) reactivation and disease after Allogenic Stem Cell Transplantation</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Donor-expanded bulk HCMV-specific CTL at a single dose on four occasions at monthly intervals, then monthly for 1 year.</interventions>
    <comparator>None (single group, unrandomised study)</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety</outcome>
      <timepoint>Assessed at the time of vaccination for up to 1 year</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Immunogenicity</outcome>
      <timepoint>Assessed at the time of vaccination for up to 1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of viral load at weekly intervals</outcome>
      <timepoint>For the first 4 months, then every 2 weeks until day 180 and then at time intervals determined by the transplantation physician.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Consenting seropositive stem cell donors and recipients, Seropositive stem cell recipients; Without severe intercurrent illness/infection requiring inpatient care, &lt;3x upper normal bilirubin, Creatinine clearance &gt;35% normal for age, Availability of well-characterised HCMV-specific CTL with minimal detectable anti-host alloreactivity.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Active intercurrent infection requiring inpatient care, Laboratory evidence of active CMV infection prior to 1st CTL infusion, ECOG status &gt;3, Positive serology for HIV, Hep B or Hep C.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>30/06/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Queensland Institute of Medical Research (QIMR)</primarysponsorname>
    <primarysponsoraddress>300 Herston Rd, Herston 4006</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Leukaemia Foundation of Australia</fundingname>
      <fundingaddress>Level 5, Mincom Central, 193 Turbot St, Brisbane 4000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Not applicable</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Since the inception of human organ transplantation, HCMV remains single most-important cause of infectious morbidity and mortality in immunocompromised transplant patients. This project is designed to develop immunotherapeutic strategies based on adoptve transfer of virus-specific killer T cells for the treatment of HCMV infection in transplant patients.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>QIMR, Herston</ethicname>
      <ethicaddress>Brisbane, QLD 4006</ethicaddress>
      <ethicapprovaldate>12/04/2002</ethicapprovaldate>
      <hrec>EC00278</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane and Womens' Hospital</ethicname>
      <ethicaddress>Herston, QLD 4029</ethicaddress>
      <ethicapprovaldate>27/03/2002</ethicapprovaldate>
      <hrec>EC00172</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Rajiv Khanna</name>
      <address>Queensland Institute of Medical Research
300 Herston Road
Herston QLD 4006</address>
      <phone>+61 7 33620385</phone>
      <fax>+61 7 38453510</fax>
      <email>Rajiv.Khanna@qimr.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Geoff Hill</name>
      <address>Queensland Institute of Medical Research 300 Herston Road
Herston QLD 4006</address>
      <phone>+61 7 38453763</phone>
      <fax>+61 7 33620107</fax>
      <email>Geoff.Hill@qimr.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Agnieszka Mitchell</name>
      <address>Queensland Institute of Medical Research, 300 Herston Rd, Herston 4006</address>
      <phone>07 3362 0241</phone>
      <fax>07 3362 0109</fax>
      <email />
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>